Have your own idea? Try our Stock Screener
Japanese (NIKKEI) Biotech Industry Analysis
UpdatedMar 16, 2026
DataAggregated Company Financials
Companies34
- 7D-7.6%
- 3M16.3%
- 1Y9.7%
- YTDn/a
Over the last 7 days, the Biotech industry has dropped 7.6%, driven by declines in 3-D Matrix and PeptiDream of 21% and 7.8%, respectively. On the other hand Pharma Foods International is actually up 17%. Over the past 12 months, the industry was up 9.7%. As for the next few years, earnings are expected to grow by 44% per annum.
Industry Valuation and Performance
Has the Japanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 17 Mar 2026 | JP¥1.2t | JP¥202.7b | -JP¥49,063,383,682.00 | 64.3x | -24.4x | 5.9x |
| Thu, 12 Feb 2026 | JP¥1.1t | JP¥198.5b | -JP¥49,866,065,000.00 | 59.8x | -22.5x | 5.7x |
| Sat, 10 Jan 2026 | JP¥1.0t | JP¥198.7b | -JP¥70,727,387,000.00 | 56.4x | -14.6x | 5.2x |
| Mon, 08 Dec 2025 | JP¥979.6b | JP¥196.3b | -JP¥69,395,659,000.00 | 48.6x | -14.1x | 5x |
| Wed, 05 Nov 2025 | JP¥1.1t | JP¥197.5b | -JP¥65,616,668,000.00 | 63.9x | -17x | 5.6x |
| Fri, 03 Oct 2025 | JP¥1.1t | JP¥197.7b | -JP¥65,794,561,000.00 | 61.2x | -16.8x | 5.6x |
| Sun, 31 Aug 2025 | JP¥1.2t | JP¥193.5b | -JP¥68,135,862,000.00 | 122.5x | -16.9x | 6x |
| Tue, 29 Jul 2025 | JP¥1.2t | JP¥218.2b | -JP¥46,531,847,000.00 | 105.7x | -25x | 5.3x |
| Thu, 26 Jun 2025 | JP¥1.2t | JP¥218.2b | -JP¥43,672,020,000.00 | 94.6x | -26.6x | 5.3x |
| Sat, 24 May 2025 | JP¥1.1t | JP¥214.8b | -JP¥40,595,527,000.00 | 14.6x | -27.3x | 5.2x |
| Mon, 21 Apr 2025 | JP¥1.1t | JP¥207.7b | -JP¥38,921,205,000.00 | 14.2x | -27.3x | 5.1x |
| Wed, 19 Mar 2025 | JP¥1.0t | JP¥207.8b | -JP¥39,285,162,000.00 | 16.2x | -26.6x | 5x |
| Fri, 14 Feb 2025 | JP¥1.0t | JP¥207.5b | -JP¥13,501,964,000.00 | 21.7x | -76x | 4.9x |
| Sun, 12 Jan 2025 | JP¥1.0t | JP¥207.3b | -JP¥13,531,081,000.00 | 21.5x | -76.9x | 5x |
| Tue, 10 Dec 2024 | JP¥1.1t | JP¥207.2b | -JP¥12,080,899,000.00 | 22.7x | -89.2x | 5.2x |
| Thu, 07 Nov 2024 | JP¥1.1t | JP¥214.4b | -JP¥3,930,528,000.00 | 22.3x | -278.1x | 5.1x |
| Sat, 05 Oct 2024 | JP¥1.1t | JP¥214.3b | -JP¥2,078,229,000.00 | 21.1x | -544x | 5.3x |
| Mon, 02 Sep 2024 | JP¥1.1t | JP¥210.1b | -JP¥469,229,000.00 | 16.9x | -2347.4x | 5.2x |
| Wed, 31 Jul 2024 | JP¥1.1t | JP¥187.7b | -JP¥15,871,901,000.00 | 92.6x | -69.5x | 5.9x |
| Fri, 28 Jun 2024 | JP¥1.0t | JP¥187.7b | -JP¥15,773,284,000.00 | 88.8x | -63.7x | 5.4x |
| Sun, 26 May 2024 | JP¥771.9b | JP¥195.7b | -JP¥14,072,545,000.00 | 92.9x | -54.9x | 3.9x |
| Tue, 23 Apr 2024 | JP¥705.7b | JP¥194.2b | -JP¥15,746,877,000.00 | 62.7x | -44.8x | 3.6x |
| Thu, 21 Mar 2024 | JP¥771.5b | JP¥194.2b | -JP¥15,457,301,000.00 | 58.4x | -49.9x | 4x |
| Sat, 17 Feb 2024 | JP¥811.8b | JP¥196.9b | -JP¥19,090,349,000.00 | 64.3x | -42.5x | 4.1x |
| Mon, 15 Jan 2024 | JP¥821.1b | JP¥222.3b | -JP¥12,668,455,000.00 | 17.6x | -64.8x | 3.7x |
| Wed, 13 Dec 2023 | JP¥736.5b | JP¥221.9b | -JP¥12,426,487,000.00 | 15.8x | -59.3x | 3.3x |
| Fri, 10 Nov 2023 | JP¥755.1b | JP¥223.0b | -JP¥11,563,085,000.00 | 20.3x | -65.3x | 3.4x |
| Sun, 08 Oct 2023 | JP¥812.4b | JP¥223.0b | -JP¥14,518,735,000.00 | 24.2x | -56x | 3.6x |
| Tue, 05 Sep 2023 | JP¥904.8b | JP¥225.1b | -JP¥19,814,131,000.00 | 48.3x | -45.7x | 4x |
| Thu, 03 Aug 2023 | JP¥900.2b | JP¥223.9b | -JP¥20,555,669,000.00 | 49.3x | -43.8x | 4x |
| Sat, 01 Jul 2023 | JP¥980.5b | JP¥223.2b | -JP¥20,138,671,000.00 | 61.2x | -48.7x | 4.4x |
| Mon, 29 May 2023 | JP¥881.1b | JP¥218.4b | -JP¥25,404,669,000.00 | 30.4x | -34.7x | 4x |
| Wed, 26 Apr 2023 | JP¥922.3b | JP¥218.1b | -JP¥20,115,522,000.00 | 21.1x | -45.9x | 4.2x |
| Fri, 24 Mar 2023 | JP¥925.2b | JP¥218.3b | -JP¥21,583,164,000.00 | 20.8x | -42.9x | 4.2x |
Price to Earnings Ratio
-42.9x
Current Industry PE
- Investors are optimistic on the Japanese Biotechnology industry, and appear confident in long term growth rates.
- The 3-year average PS ratio of 4.7x is lower than the industry's current PS ratio of 5.9x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
- Revenues have also declined 2.4% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Comparison
How does Japanese Biotech compare with similar industries?
| JP Market | -2.28% | |
| Healthcare | -1.31% | |
| Biotech | -7.63% | |
| Biotech | -7.63% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 2929 Pharma Foods International | JP¥672.00 | 17.5% +JP¥2.9b | -28.1% | PS0.3x | |
| 4893 Noile-Immune Biotech | JP¥205.00 | 40.4% +JP¥2.6b | 21.3% | PS1775.4x | |
| 504A Innovacell | JP¥1.03k | 4.3% +JP¥1.8b | n/a | PE-15.1x | |
| 4599 StemRIM | JP¥305.00 | 5.2% +JP¥940.2m | -10.6% | PB2.9x | |
| 4594 BrightPath Biotherapeutics | JP¥72.00 | 10.8% +JP¥922.4m | 63.6% | PS8809x |
